Infliximab and reactivation of cerebral toxoplasmosis.
Young
Jeremy D
JD
McGwire
Bradford S
BS
D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001921:Brain / Q000473:pathology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D009894:Opportunistic Infections / Q000209:etiology; D014122:Toxoplasma / Q000187:drug effects / Q000502:physiology*; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014775:Virus Activation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab